Association of a CYP4A11 variant and blood pressure in black men.
暂无分享,去创建一个
M. Waterman | J. Capdevila | N. Brown | E. Dawson | M. Lipkowitz | J. Gainer | Chang Yu
[1] T. Nakayama,et al. A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men , 2008, Journal of hypertension.
[2] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[3] H. Baelde,et al. Genetic factors in progressive renal disease: the good ones, the bad ones and the ugly ducklings. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] I. König,et al. Association of the T8590C Polymorphism of CYP4A11 With Hypertension in the MONICA Augsburg Echocardiographic Substudy , 2005, Hypertension.
[5] Keith C. Norris,et al. Unraveling the racial disparities associated with kidney disease. , 2005, Kidney international.
[6] B. Freedman,et al. Genetic factors in end-stage renal disease. , 2005, Kidney international. Supplement.
[7] M. Waterman,et al. Functional Variant of CYP4A11 20-Hydroxyeicosatetraenoic Acid Synthase Is Associated With Essential Hypertension , 2005, Circulation.
[8] L. Appel,et al. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. , 2004, Journal of the American Society of Nephrology : JASN.
[9] M. Wellner,et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. , 2004, The American journal of pathology.
[10] Josef Coresh,et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. , 2003, Journal of the American Society of Nephrology : JASN.
[11] M. Kutner,et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). , 2003, Journal of the American Society of Nephrology : JASN.
[12] Keith C. Norris,et al. The rationale and design of the AASK cohort study. , 2003, Journal of the American Society of Nephrology : JASN.
[13] A. Nasjletti,et al. Differential Regulation of Natriuresis by 20-Hydroxyeicosatetraenoic Acid in Human Salt-Sensitive Versus Salt-Resistant Hypertension , 2003, Circulation.
[14] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[15] N. Kaplan,et al. On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles , 2002, Genetic epidemiology.
[16] J. Lewis,et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[18] J. Falck,et al. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. , 2001, Biochemical and biophysical research communications.
[19] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[20] R. Roman,et al. Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. , 2001, American journal of hypertension.
[21] M. Waterman,et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Mcgiff,et al. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure , 2001, Current opinion in nephrology and hypertension.
[23] H. Jacob,et al. Evidence of gene-gene interactions in the genetic susceptibility to renal impairment after unilateral nephrectomy. , 2000, Journal of the American Society of Nephrology : JASN.
[24] M. Carroll,et al. A new class of lipid mediators: cytochrome P450 arachidonate metabolites , 2000, Thorax.
[25] G. Bakris,et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] J. Falck,et al. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. , 2000, American journal of physiology. Heart and circulatory physiology.
[27] J. Mcgiff,et al. 20-HETE and the kidney: resolution of old problems and new beginnings. , 1999, The American journal of physiology.
[28] J. Coresh,et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] R. Roman,et al. Increased excretion of urinary 20-HETE in rats with cyclosporine-induced nephrotoxicity. , 2005, Journal of pharmacological sciences.
[30] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] R. Roman,et al. P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.
[32] C. Lewis,et al. A genome scan for renal function among hypertensives: the HyperGEN study. , 2001, American journal of human genetics.
[33] M. Daly,et al. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat , 1996, Nature Genetics.